

# red-stars.com data AG group: Highlights 1<sup>st</sup> Half 2023

Vienna, August 3<sup>rd</sup>, 2023

- MAVOCO: revenue H1 23/22: + 275%
- Txture: Q2/2023: best quarter in the company's history; H1 23/22: + 26%
- ecosio: H1 23/22: + 24.6%
- Freeway: strategic investors and buyers expressing strong interest
- a:head: pre-Series A financing
- HeartBeat: imminent commissioning of high-throughput organoid production
- Rockfish: very promising data on senescence reduction in preclinical models
- red-stars: Wolfgang Hesoun (former CEO Siemens) joined the supervisory board

**MAVOCO:** Successful completion of the Telkomsel/Indonesia project (complete replacement of Cisco Jasper by migrating to the MAVOCO platform) with final acceptance by the end user and the partner Amdocs as well as full payment. Encouraging project progress at Zain in Saudi Arabia and Kuwait. Strong pipeline for new projects in South America, Asia, USA, Scandinavia, Netherlands, and Austria.

**Txture:** Best Q2 in the company's history with projects implemented for Google Cloud, AMD, Intel, Amazon Web Services, ÖBB, A1, and voestalpine, among others. Strong interest from financing partners and strategic investors. Austria Wirtschaftsservice "Eigenkapital Hebeln" loan financing closed. Through a new partnership, Txture will address the telecommunications segment and its global cloud transformation and optimization opportunities.

**ecosio:** Several new customers from the machinery, automotive, consumer goods, and manufacturing industries lay the foundation for strong growth. Strong expansion of existing customer business, such as the contract extension with MIGROS. In addition to EDI, electronic invoicing is developing well, mainly due to new legislation. Contracts have been secured for Poland, Luxembourg, and Belgium. The churn rate remains below 0.1% per month. Geographical expansion is heading towards France, Spain, and Scandinavia, in particular focusing on e-invoicing and Peppol. A further increase of business is expected in 2nd half of 2023, as several major deals are about to be signed.

**Freeway:** Growth in the industrial segment (B2B) compensated for lower demand in the consumer segment (B2C). New customers in all industrial segments, notably LG Electronics Iberia for Smart Home applications and Mann+Hummel for projects in the automotive supplier industry. First customer in Freeway's IoT Monetization Hub with Alarm-Automatika billing connectivity for home alarm systems for their distribution partners. Positive project development with ALSO, particularly with Seamcom. Gross margin around 60%, ARPU far ahead of industry benchmarks. Strong interest from strategic investors.



**TTTech:** Divestment closed with marginal profit.

**a:head:** Pre-Series A financing successfully completed with renowned investors - first closing in September 2023. Due to strong interest, expansion planned for October 2023. Ongoing Series A talks with international VCs. Approved epilepsy drugs show effectiveness in the organoid epilepsy model, and promising results of clinically used CNS medications are available. Non-invasive, AI-supported quality control and automation feasibility demonstrated. Data pipelines for processing and analyzing various data modalities from organoid production to network activity measurement implemented. Discussions with pharma on potential collaborations.

**HeartBeat:** As part of the collaboration with Molecular Devices, the first prototype for high-throughput will be available in Q3/2023. Monthly output of up to 50,000 cardioids planned in 2024. Proof of concept and first applications are on the way with two industry partners. Pre-Series A financing in negotiation with multiple investors totaling EUR 4.5 million.

**Rockfish:** First data of senolytic treatment with the lead candidate RFB01016 in old mice validating reduction in senescent cells and significant improvement in physiological functions related to strength, endurance, agility, wound healing, and reduction of various pathologies. Preparations for lead optimization and initial disease models have been made.

**red-stars:** At the Annual General Meeting on July 13, 2023, Wolfgang Hesoun (former CEO Siemens) and Christian Meixner (former Austrian Institute of Technology) were newly elected to the supervisory board. The board is now headed by Albert Birkner as the chairman.

Contact:

Thomas Streimelweger, CEO  
[t.streimelweger@red-stars.com](mailto:t.streimelweger@red-stars.com)  
+43 664 340 26 78

Georg Schoder, CFO  
[g.schoder@red-stars.com](mailto:g.schoder@red-stars.com)  
+43 664 301 59 44

**Digitalization & Life Sciences**

[www.red-stars.com](http://www.red-stars.com)